VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Influenza virus DNA vaccine M2-DNA/M2-Ad
Vaccine Information
  • Vaccine Name: Influenza virus DNA vaccine M2-DNA/M2-Ad
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004568
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1)) gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000334
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Baboon Response

  • Vaccination Protocol: DNA vaccination at doses of 50 μg/mouse in low-endotoxin PBS was given intramuscularly in the quadriceps, half to each leg, in 3 doses 2 weeks apart. In some experiments, mice were given a booster injection of rAd intramuscularly at a dose of 1010 particles/mouse, 2–3 weeks after the last dose of DNA (Tompkins et al., 2007).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Mice primed with M2-DNA and then boosted with recombinant adenovirus expressing M2 (M2-Ad) had enhanced antibody responses that cross-reacted with human and avian M2 sequences and induced T-cell responses (Tompkins et al., 2007).
  • Challenge Protocol: Challenge virus in 50 μL of PBS was administered intranasally to anesthetized mice. Isoflurane or ketamine/xylazine was used for mice challenged with H1N1 subtype. Subtype H5N1 was administered intranasally to mice anesthetized with 2,2,2-tribromoethanol in tert-amyl alcohol (Tompkins et al., 2007).
  • Efficacy: Of mice vaccinated with M2-DNA, 100% survived challenge with A/PR/8 and A/FM virus, both subtypes of the H1N1 virus (Tompkins et al., 2007).
References
Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].